Protagonist Therapeutics (PTGX) Stock Forecast, Price Target & Predictions
PTGX Stock Forecast
Protagonist Therapeutics stock forecast is as follows: an average price target of $50.00 (represents a 6.34% upside from PTGX’s last price of $47.02) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
PTGX Price Target
The average price target for Protagonist Therapeutics (PTGX) is $50.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $50.00 to $50.00. This represents a potential 6.34% upside from PTGX's last price of $47.02.
PTGX Analyst Ratings
According to 4 Wall Street analysts, Protagonist Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for PTGX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Protagonist Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 12, 2024 | Douglas Tsao | H.C. Wainwright | $50.00 | $45.08 | 10.91% | 6.34% |
| Jun 17, 2024 | Douglas Tsao | H.C. Wainwright | $38.00 | $32.86 | 15.64% | -19.18% |
The latest Protagonist Therapeutics stock forecast, released on Sep 12, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $50.00, which represents a 10.91% increase from the stock price at the time of the forecast ($45.08), and a 6.34% increase from PTGX last price ($47.02).
Protagonist Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 2 |
| Avg Price Target | $50.00 | $44.00 | $44.00 |
| Last Closing Price | $47.02 | $47.02 | $47.02 |
| Upside/Downside | 6.34% | -6.42% | -6.42% |
In the current month, the average price target of Protagonist Therapeutics stock is $50.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 6.34% increase as opposed to Protagonist Therapeutics's last price of $47.02. This month's average price target is up 13.64% compared to last quarter, and up 13.64% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 24, 2024 | BTIG | Buy | Buy | Hold |
| Jun 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 06, 2023 | JMP Securities | Market Outperform | Market Outperform | Hold |
| May 17, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Protagonist Therapeutics's last stock rating was published by H.C. Wainwright on Sep 12, 2024. The company gave PTGX a "Buy" rating, the same as its previous rate.
Protagonist Therapeutics Financial Forecast
Protagonist Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $25.72M | $8.62M | $10.29M | $2.27M | $6.19M | $5.65M | $13.11M | $6.22M | $3.65M | $2.72M | $4.14M | $-8.19M | $1.56M | $6.12M | $11.67M |
| Avg Forecast | $57.50M | $7.50M | $100.00M | $5.60M | $47.20M | $1.00M | $3.14M | $262.50M | $60.00M | $10.00M | $355.30K | $2.00M | $3.33M | $1.90M | $460.00K | $21.18M | $5.07M | $1.74M | $5.17M | $1.50M | $2.70M | $2.87M | $2.95M | $1.48M | $4.23M | $4.83M | $11.20M | $4.89M | $5.96M | $9.97M |
| High Forecast | $57.50M | $7.50M | $100.00M | $5.60M | $47.20M | $1.00M | $3.14M | $262.50M | $60.00M | $10.00M | $426.36K | $2.00M | $3.33M | $2.28M | $460.00K | $21.18M | $5.07M | $1.74M | $5.17M | $1.50M | $2.70M | $2.87M | $2.95M | $1.48M | $4.23M | $4.83M | $11.20M | $4.89M | $7.15M | $11.96M |
| Low Forecast | $57.50M | $7.50M | $100.00M | $5.60M | $47.20M | $1.00M | $3.14M | $262.50M | $60.00M | $10.00M | $284.24K | $2.00M | $3.33M | $1.52M | $460.00K | $21.18M | $5.07M | $1.74M | $5.17M | $1.50M | $2.70M | $2.87M | $2.95M | $1.48M | $4.23M | $4.83M | $11.20M | $4.89M | $4.76M | $7.97M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 5 | 15 | 10 | 9 | 20 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 7 | 4 | 4 | 8 | 5 | 11 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.21% | 1.70% | 5.90% | 0.44% | 4.13% | 2.09% | 4.57% | 2.11% | 2.46% | 0.64% | 0.86% | -0.73% | 0.32% | 1.03% | 1.17% |
Protagonist Therapeutics's average Quarter revenue forecast for Jul 22 based on 9 analysts is $460.00K, with a low forecast of $460.00K, and a high forecast of $460.00K. PTGX's average Quarter revenue forecast represents a -98.21% decrease compared to the company's last Quarter revenue of $25.72M (Mar 22).
Protagonist Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 5 | 15 | 10 | 9 | 20 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 7 | 4 | 4 | 8 | 5 | 11 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-36.02M | $-36.52M | $-31.45M | - | $-20.28M | $-36.09M | $-33.10M | $-30.21M | $-23.37M | $-18.13M | $-7.12M | $-17.44M | $-19.00M | $-15.83M | $-15.87M | $-30.18M | $-13.33M | $-8.58M | $-8.49M |
| Avg Forecast | $-57.50M | $-7.50M | $-100.00M | $-5.60M | $-47.20M | $-1.00M | $-3.14M | $-22.95M | $-60.00M | $-27.64M | $-41.17M | $-24.55M | $-3.33M | $-29.56M | $-460.00K | $-26.26M | $-36.55M | $-31.62M | $-26.80M | $-24.60M | $-2.70M | $-10.61M | $-16.85M | $-18.17M | $-4.23M | $-18.11M | $-60.15M | $-13.56M | $-8.35M | $-7.04M |
| High Forecast | $-57.50M | $-7.50M | $-100.00M | $-5.60M | $-47.20M | $-1.00M | $-3.14M | $-18.36M | $-60.00M | $-22.11M | $-32.94M | $-19.64M | $-3.33M | $-23.65M | $-460.00K | $-21.00M | $-29.24M | $-25.29M | $-21.44M | $-19.68M | $-2.70M | $-8.49M | $-13.48M | $-14.54M | $-4.23M | $-14.49M | $-48.12M | $-10.85M | $-6.68M | $-5.63M |
| Low Forecast | $-57.50M | $-7.50M | $-100.00M | $-5.60M | $-47.20M | $-1.00M | $-3.14M | $-27.54M | $-60.00M | $-33.17M | $-49.40M | $-29.46M | $-3.33M | $-35.48M | $-460.00K | $-31.51M | $-43.86M | $-37.94M | $-32.16M | $-29.53M | $-2.70M | $-12.73M | $-20.22M | $-21.81M | $-4.23M | $-21.73M | $-72.18M | $-16.27M | $-10.02M | $-8.44M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.47% | 10.95% | 1.06% | - | 0.77% | 0.99% | 1.05% | 1.13% | 0.95% | 6.71% | 0.67% | 1.04% | 1.05% | 3.74% | 0.88% | 0.50% | 0.98% | 1.03% | 1.21% |
undefined analysts predict PTGX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Protagonist Therapeutics's previous annual EBITDA (undefined) of $NaN.
Protagonist Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 5 | 15 | 10 | 9 | 20 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 7 | 4 | 4 | 8 | 5 | 11 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-31.43M | $-31.29M | $-30.16M | - | $-20.75M | $-36.91M | $-33.80M | $-30.84M | $-24.00M | $-18.89M | $-7.76M | $-19.42M | $-20.08M | $-17.50M | $-16.41M | $-29.17M | $-14.10M | $-8.73M | $-8.66M |
| Avg Forecast | $-11.65M | $-42.10M | $12.87M | $-34.33M | $-6.32M | $-36.69M | $-36.50M | $-24.11M | $3.29M | $-28.23M | $-42.08M | $-25.78M | $-40.96M | $-30.19M | $-59.48M | $-27.57M | $-37.38M | $-32.29M | $-27.36M | $-25.26M | $-29.54M | $-11.57M | $-18.76M | $-19.21M | $-40.04M | $-18.72M | $-58.14M | $-14.34M | $-8.50M | $-7.18M |
| High Forecast | $-11.65M | $-42.10M | $12.87M | $-34.33M | $-6.32M | $-29.47M | $-36.50M | $-19.29M | $14.18M | $-22.58M | $-33.67M | $-20.63M | $-40.96M | $-24.15M | $-59.48M | $-22.06M | $-29.90M | $-25.83M | $-21.89M | $-20.21M | $-29.54M | $-9.25M | $-15.01M | $-15.37M | $-40.04M | $-14.98M | $-46.51M | $-11.47M | $-6.80M | $-5.74M |
| Low Forecast | $-11.65M | $-42.10M | $12.87M | $-34.33M | $-6.32M | $-42.71M | $-36.50M | $-28.93M | $-7.60M | $-33.87M | $-50.50M | $-30.94M | $-40.96M | $-36.23M | $-59.48M | $-33.09M | $-44.86M | $-38.75M | $-32.83M | $-30.31M | $-29.54M | $-13.88M | $-22.52M | $-23.05M | $-40.04M | $-22.46M | $-69.77M | $-17.21M | $-10.20M | $-8.61M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.22% | 0.76% | 1.00% | - | 0.75% | 0.99% | 1.05% | 1.13% | 0.95% | 0.64% | 0.67% | 1.04% | 1.05% | 0.44% | 0.88% | 0.50% | 0.98% | 1.03% | 1.21% |
Protagonist Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PTGX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Protagonist Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 5 | 15 | 10 | 9 | 20 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 7 | 4 | 4 | 8 | 5 | 11 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $8.61M | $6.63M | $6.90M | - | $10.52M | $7.26M | $7.26M | $6.71M | $5.96M | $4.99M | $4.89M | $4.18M | $4.58M | $4.11M | $4.01M | $3.86M | $3.76M | $3.36M | $3.18M |
| Avg Forecast | $823.11M | $107.36M | $1.43B | $80.11M | $675.67M | $14.31M | $44.97M | $12.11M | $858.90M | $6.06M | $5.09M | $28.63M | $47.72M | $27.17M | $6.58M | $13.85M | $72.60M | $24.95M | $74.03M | $21.47M | $38.65M | $41.04M | $42.23M | $21.19M | $60.52M | $4.58M | $7.70M | $3.83M | $3.27M | $2.63M |
| High Forecast | $823.11M | $107.36M | $1.43B | $80.11M | $675.67M | $14.31M | $44.97M | $14.53M | $858.90M | $7.27M | $6.10M | $28.63M | $47.72M | $32.60M | $6.58M | $16.62M | $72.60M | $24.95M | $74.03M | $21.47M | $38.65M | $41.04M | $42.23M | $21.19M | $60.52M | $5.50M | $9.24M | $4.59M | $3.92M | $3.16M |
| Low Forecast | $823.11M | $107.36M | $1.43B | $80.11M | $675.67M | $14.31M | $44.97M | $9.69M | $858.90M | $4.85M | $4.07M | $28.63M | $47.72M | $21.74M | $6.58M | $11.08M | $72.60M | $24.95M | $74.03M | $21.47M | $38.65M | $41.04M | $42.23M | $21.19M | $60.52M | $3.66M | $6.16M | $3.06M | $2.62M | $2.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.30% | 0.14% | 0.25% | - | 0.76% | 0.10% | 0.29% | 0.09% | 0.28% | 0.13% | 0.12% | 0.10% | 0.22% | 0.07% | 0.88% | 0.50% | 0.98% | 1.03% | 1.21% |
Protagonist Therapeutics's average Quarter SG&A projection for Jul 23 is $5.09M, based on 15 Wall Street analysts, with a range of $4.07M to $6.10M. The forecast indicates a -40.89% fall compared to PTGX last annual SG&A of $8.61M (Mar 23).
Protagonist Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 5 | 15 | 10 | 9 | 20 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 7 | 4 | 4 | 8 | 5 | 11 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.62 | $-0.64 | $-0.61 | - | $-0.43 | $-0.77 | $-0.70 | $-0.69 | $-0.54 | $-0.48 | $-0.21 | $-0.59 | $-0.72 | $-0.63 | $-0.61 | $-1.18 | $-0.58 | $-0.38 | $-0.41 |
| Avg Forecast | $-0.19 | $-0.69 | $0.21 | $-0.56 | $-0.10 | $-0.60 | $-0.60 | $3.37 | $0.05 | $-0.66 | $-0.67 | $-0.73 | $-0.67 | $-0.87 | $-0.94 | $-0.54 | $-0.78 | $-0.67 | $-0.55 | $-0.57 | $-0.48 | $-0.61 | $-0.56 | $-0.69 | $-0.65 | $-0.71 | $-0.28 | $-0.59 | $-0.36 | $-0.29 |
| High Forecast | $-0.19 | $-0.69 | $0.21 | $-0.56 | $-0.10 | $-0.48 | $-0.60 | $3.37 | $0.23 | $-0.66 | $-0.67 | $-0.73 | $-0.67 | $-0.87 | $-0.94 | $-0.54 | $-0.78 | $-0.67 | $-0.55 | $-0.57 | $-0.48 | $-0.61 | $-0.56 | $-0.69 | $-0.65 | $-0.71 | $-0.28 | $-0.59 | $-0.29 | $-0.23 |
| Low Forecast | $-0.19 | $-0.69 | $0.21 | $-0.56 | $-0.10 | $-0.70 | $-0.60 | $3.37 | $-0.12 | $-0.67 | $-0.67 | $-0.73 | $-0.67 | $-0.87 | $-0.94 | $-0.54 | $-0.78 | $-0.67 | $-0.55 | $-0.57 | $-0.48 | $-0.61 | $-0.56 | $-0.69 | $-0.65 | $-0.71 | $-0.28 | $-0.59 | $-0.43 | $-0.35 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.85% | 0.96% | 0.70% | - | 0.80% | 0.98% | 1.04% | 1.26% | 0.95% | 1.00% | 0.34% | 1.04% | 1.04% | 0.97% | 0.86% | 4.21% | 0.99% | 1.06% | 1.41% |
According to undefined Wall Street analysts, Protagonist Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PTGX previous annual EPS of $NaN (undefined).
Protagonist Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.29 | $33.86 | 1378.60% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| MRUS | Merus | $50.14 | $77.86 | 55.29% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| KURA | Kura Oncology | $20.88 | $28.67 | 37.31% | Buy |
| IDYA | IDEAYA Biosciences | $37.46 | $46.13 | 23.14% | Buy |
| RNA | Avidity Biosciences | $41.71 | $50.00 | 19.88% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| VRNA | Verona Pharma | $29.78 | $33.00 | 10.81% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
PTGX Forecast FAQ
Is Protagonist Therapeutics a good buy?
Yes, according to 4 Wall Street analysts, Protagonist Therapeutics (PTGX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of PTGX's total ratings.
What is PTGX's price target?
Protagonist Therapeutics (PTGX) average price target is $50 with a range of $50 to $50, implying a 6.34% from its last price of $47.02. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Protagonist Therapeutics stock go up soon?
According to Wall Street analysts' prediction for PTGX stock, the company can go up by 6.34% (from the last price of $47.02 to the average price target of $50), up by 6.34% based on the highest stock price target, and up by 6.34% based on the lowest stock price target.
Can Protagonist Therapeutics stock reach $70?
PTGX's average twelve months analyst stock price target of $50 does not support the claim that Protagonist Therapeutics can reach $70 in the near future.
What is Protagonist Therapeutics's current price target trend?
1 Wall Street analyst forecast a $50 price target for Protagonist Therapeutics (PTGX) this month, up 6.34% from its last price of $47.02. Compared to the last 3 and 12 months, the average price target decreased by -6.42% and decreased by -6.42%, respectively.
What are Protagonist Therapeutics's analysts' financial forecasts?
Protagonist Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $313.84M (high $313.84M, low $313.84M), average EBITDA is $-74.295M (high $-69.704M, low $-78.886M), average net income is $-104M (high $-91.577M, low $-114M), average SG&A $747.07M (high $749.49M, low $744.64M), and average EPS is $2.07 (high $2.19, low $1.97). PTGX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $170.6M (high $170.6M, low $170.6M), average EBITDA is $-171M (high $-171M, low $-171M), average net income is $-75.201M (high $-75.201M, low $-75.201M), average SG&A $2.44B (high $2.44B, low $2.44B), and average EPS is $-1.227 (high $-1.227, low $-1.227).
Did the PTGX's actual financial results beat the analysts' financial forecasts?
Based on Protagonist Therapeutics's last annual report (Dec 2023), the company's revenue was $60M, which missed the average analysts forecast of $72.36M by -17.08%. Apple's EBITDA was $-93.652M, missing the average prediction of $-153M by -38.93%. The company's net income was $-78.955M, missing the average estimation of $-92.807M by -14.93%. Apple's SG&A was $33.49M, missing the average forecast of $898.67M by -96.27%. Lastly, the company's EPS was $-0.0014, missing the average prediction of $-2 by -99.93%. In terms of the last quarterly report (Mar 2022), Protagonist Therapeutics's revenue was $25.72M, beating the average analysts' forecast of $21.18M by 21.43%. The company's EBITDA was $-20.278M, missing the average prediction of $-26.256M by -22.77%. Protagonist Therapeutics's net income was $-20.749M, missing the average estimation of $-27.574M by -24.75%. The company's SG&A was $10.52M, missing the average forecast of $13.85M by -24.10%. Lastly, the company's EPS was $-0.43, missing the average prediction of $-0.54 by -20.35%